USPTO 2015–2025 USPTO PatentsView US Corporation

Johnson & Johnson Vision Care, Inc.

USPTO PatentsView assignee record - 543 granted patents across 87 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: G02C (SPECTACLES; Sunglasses OR Goggles Insofar AS They Have THE Same Features AS SPECTACLES; Contact Lenses).

RSS updates for this company

The verdict

According to USPTO PatentsView, Johnson ranks #840 of 49,997 tracked US assignees by granted-patent volume, with 543 patents across 87 technology areas.

#840
of 49,997 US assignees by volume
Top 3%
by Innovation Score (60.6/100)
17.6
avg claims per patent
-61%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R840 · US Corporation #840 · 543 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MID 543 grants
  • TOP-DECILE #840/49,997
  • PHOTO-FINISH Aisin
  • CPC-WIDE G02C · 87 areas
  • INNOV-STRONG 60.6/100
  • CLAIMS-RICH 17.6 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -61% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Aisin Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Johnson

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Johnson's Innovation Score is 60.6/100 (top 3% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

How Johnson's grant cadence moved

Between 2020–2024, Johnson & Johnson Vision Care, Inc. received 149 grants versus 379 in 2015–2019 (-61% equal-window velocity, below median growth). Across complete PatentsView years, output peaked in 2016 at 86 grants and bottomed in 2022 at 20. Lead class G02C accounts for 66.3% of the portfolio across 87 subclasses. Volume neighbours: Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. (#836) and Siemens Healthcare Diagnostics Inc. (#844).

Johnson's three-year grant acceleration

From 2019–2021 to 2022–2024, Johnson & Johnson Vision Care, Inc. moved from 145 to 72 grants (0.50x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,704. See the growth leaderboard.

Who files at Johnson's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Johnson holds 543 patents at rank #840, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Johnson

By rank, the assignees closest to #840 in granted patent volume.

Leaders in G02C (Spectacles)

Other assignees with the most granted patents in Johnson's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Johnson, neither rank-band nor same-CPC leaders (those blocks stay above).

Johnson's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

61 Top 3% higher than 97% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

020406080100 20152016201720182019202020212022202320242025 15
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Johnson & Johnson Vision Care, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 74 13.6%
2016 86 15.8%
2017 84 15.5%
2018 67 12.3%
2019 68 12.5%
2020 40 7.4%
2021 37 6.8%
2022 20 3.7%
2023 27 5.0%
2024 25 4.6%
2025partial year 15 2.8%

Which technologies does Johnson & Johnson Vision Care, Inc. patent most?

Top 15 of 87 technology areas

Where it ranks

Overall rank by patents

#840

of 49,997 tracked assignees

Innovation Score

60.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Johnson & Johnson Vision Care, Inc.'s patent record in context - here's where to go next.

  • Johnson & Johnson Vision Care, Inc.'s lead technology class is G02C (SPECTACLES; Sunglasses OR Goggles Insofar AS They Have THE Same Features AS SPECTACLES; Contact Lenses), 66.3% of its portfolio - see every assignee active in that class. Explore G02C
  • Ranked #840 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Johnson & Johnson Vision Care, Inc. against Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 60.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.